The GLP-1 economy: How weight-loss drugs are impacting major industries The popularization of drugs like Ozempic is shifting the way consumers spend and forcing businesses to adapt Weight-loss drugs like Ozempic have undoubtedly made their mark on healthcare
A population-based cohort study of nearly 114,000 patients with T2D found that use of GLP-1s, compared with SGLT-2 inhibitors, was associated with a 27% higher relative risk of being diagnosed with GERD and a 55% higher relative risk of GERD-related complications
The standard dosing regimens have been established through extensive pharmacokinetic and pharmacodynamic studies, ensuring that therapeutic drug levels are achieved and maintained
However, this is where many wellness routines fall short
A systematic review of 17 clinical studies involving over 25,000 subjects showed that increased systemic TMAO concentrations were correlated with higher cardiovascular events, and the relative risk of all-cause mortality was shown to increase by 7.6% per 10 mol/L increments of plasma TMAO concentration (Schiattarella et al., 2017)
